Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DOCS Stock Forecast 2025-2026
$45.04
Current Price
$8.48B
Market Cap
Buy 11
Hold 7
Sell 2
Wall St Analyst Ratings
Distance to DOCS Price Targets
+84.3%
To High Target of $83.00
+44.3%
To Median Target of $65.00
+22.1%
To Low Target of $55.00
DOCS Price Momentum
-12.2%
1 Week Change
-14.6%
1 Month Change
-14.3%
1 Year Change
-15.6%
Year-to-Date Change
-47.1%
From 52W High of $85.21
+0.7%
From 52W Low of $44.71
📊 TOP ANALYST CALLS
Did DOCS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Doximity is one of their latest high-conviction picks.
Latest DOCS Stock Price Targets & Analyst Predictions
Based on our analysis of 29 Wall Street analysts, DOCS has a bullish consensus with a median price target of $65.00 (ranging from $55.00 to $83.00). The overall analyst rating is Buy (7.6/10). Currently trading at $45.04, the median forecast implies a 44.3% upside. This outlook is supported by 11 Buy, 7 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Brian Peterson at Raymond James, projecting a 84.3% upside. Conversely, the most conservative target is provided by Sean Dodge at BMO Capital, suggesting a 22.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DOCS Analyst Ratings
11
Buy
7
Hold
2
Sell
DOCS Price Target Range
Low
$55.00
Average
$65.00
High
$83.00
Current: $45.04
Latest DOCS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DOCS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $63.00 |
| Nov 21, 2025 | Raymond James | Brian Peterson | Strong Buy | Upgrade | $65.00 |
| Nov 13, 2025 | BMO Capital | Sean Dodge | Market Perform | Initiates | $55.00 |
| Nov 10, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $58.00 |
| Nov 7, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $70.00 |
| Oct 27, 2025 | B of A Securities | Allen Lutz | Buy | Upgrade | $82.00 |
| Oct 10, 2025 | JP Morgan | Alexei Gogolev | Underweight | Downgrade | $62.00 |
| Oct 8, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $81.00 |
| Oct 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $80.00 |
| Oct 1, 2025 | Goldman Sachs | David Roman | Sell | Downgrade | $64.00 |
| Sep 18, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $67.00 |
| Sep 11, 2025 | Baird | Vikram Kesavabhotla | Outperform | Maintains | $80.00 |
| Aug 11, 2025 | Piper Sandler | Jessica Tassan | Overweight | Maintains | $69.00 |
| Aug 8, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $75.00 |
| Aug 8, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $59.00 |
| Aug 8, 2025 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $65.00 |
| Aug 8, 2025 | Raymond James | Brian Peterson | Outperform | Maintains | $75.00 |
| Aug 4, 2025 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $62.00 |
| Jul 17, 2025 | Truist Securities | Jailendra Singh | Hold | Maintains | $61.00 |
| Jul 14, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $70.00 |
Doximity Inc. (DOCS) Competitors
The following stocks are similar to Doximity based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Doximity Inc. (DOCS) Financial Data
Doximity Inc. has a market capitalization of $8.48B with a P/E ratio of 36.1x. The company generates $621.33M in trailing twelve-month revenue with a 40.7% profit margin.
Revenue growth is +23.2% quarter-over-quarter, while maintaining an operating margin of +38.5% and return on equity of +24.6%.
Valuation Metrics
Market Cap
$8.48B
Enterprise Value
$7.73B
P/E Ratio
36.1x
PEG Ratio
1.0x
Price/Sales
13.7x
Growth & Margins
Revenue Growth (YoY)
+23.2%
Gross Margin
+90.3%
Operating Margin
+38.5%
Net Margin
+40.7%
EPS Growth
+40.6%
Financial Health
Cash/Price Ratio
+10.4%
Current Ratio
7.8x
Debt/Equity
1.0x
ROE
+24.6%
ROA
+13.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Doximity Inc. (DOCS) Business Model
About Doximity Inc.
What They Do
Digital platform for medical professionals.
Business Model
Doximity generates revenue primarily through subscription services and advertising targeted at healthcare professionals. By offering a suite of tools for communication, networking, and telehealth, the company capitalizes on the growing demand for digital solutions in healthcare, enabling providers to enhance their practice and connect with peers.
Additional Information
Founded to improve collaboration within the healthcare community, Doximity's platform includes features like a secure social networking site, telehealth services, and career resources for healthcare professionals. The company's emphasis on digitization highlights its role in transforming the healthcare landscape and promoting efficient information exchange.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
830
CEO
Mr. Jeffrey A. Tangney
Country
United States
IPO Year
2021
Website
www.doximity.comDoximity Inc. (DOCS) Latest News & Analysis
Latest News
Quick Summary
Doximity's Q2 results indicate record engagement and increased AI tool adoption. Revenue is improving with pharma clients favoring long-term programs. The company has high margins, $890M cash, and no debt.
Why It Matters
Doximity's strong Q2 results, increasing AI adoption, and improved revenue from pharma indicate robust growth potential, solid financial health, and a favorable market position, boosting investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
The Zacks Style Scores help investors identify top-rated stocks aligned with their investing style, providing an efficient tool for stock selection.
Why It Matters
Zacks Style Scores provide a streamlined method for identifying high-potential stocks, aiding investment decisions and enhancing portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CVNA last traded at $313.25, having found support at $285.02, which is a double-bottom support level from June 2025.
Why It Matters
CVNA's share price showing support at $285.02 indicates potential stability and recovery, suggesting a favorable entry point for investors looking at future growth.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
The mention of Zacks Style Scores highlights a tool for identifying high-potential stocks, potentially guiding investors to outperform the market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Doximity, Inc. will host its Q2 2026 earnings call on November 6, 2025, at 5:00 PM EST, featuring key company executives and analysts from various firms.
Why It Matters
Doximity's upcoming earnings call will provide insights into financial performance and strategic direction, crucial for assessing investment potential and market confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Doximity, Inc. reported Q2 fiscal 2026 results, with 650,000 prescribers using their tools. AI Scribe and DoxGPT user growth exceeded 50% from the previous quarter.
Why It Matters
Doximity's growth in user engagement and AI tool adoption signals strong demand for its services, potentially enhancing revenue and market position, which can positively influence stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About DOCS Stock
What is Doximity Inc.'s (DOCS) stock forecast for 2026?
Based on our analysis of 29 Wall Street analysts, Doximity Inc. (DOCS) has a median price target of $65.00. The highest price target is $83.00 and the lowest is $55.00.
Is DOCS stock a good investment in 2026?
According to current analyst ratings, DOCS has 11 Buy ratings, 7 Hold ratings, and 2 Sell ratings. The stock is currently trading at $45.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DOCS stock?
Wall Street analysts predict DOCS stock could reach $65.00 in the next 12 months. This represents a 44.3% increase from the current price of $45.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Doximity Inc.'s business model?
Doximity generates revenue primarily through subscription services and advertising targeted at healthcare professionals. By offering a suite of tools for communication, networking, and telehealth, the company capitalizes on the growing demand for digital solutions in healthcare, enabling providers to enhance their practice and connect with peers.
What is the highest forecasted price for DOCS Doximity Inc.?
The highest price target for DOCS is $83.00 from Brian Peterson at Raymond James, which represents a 84.3% increase from the current price of $45.04.
What is the lowest forecasted price for DOCS Doximity Inc.?
The lowest price target for DOCS is $55.00 from Sean Dodge at BMO Capital, which represents a 22.1% increase from the current price of $45.04.
What is the overall DOCS consensus from analysts for Doximity Inc.?
The overall analyst consensus for DOCS is bullish. Out of 29 Wall Street analysts, 11 rate it as Buy, 7 as Hold, and 2 as Sell, with a median price target of $65.00.
How accurate are DOCS stock price projections?
Stock price projections, including those for Doximity Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 9:27 AM UTC